Performance evaluation of ABH-PA
- Conditions
- Chronic Kidney DiseaseKidney Disease
- Registration Number
- JPRN-jRCTs062190020
- Lead Sponsor
- OKADA Kazuyoshi
- Brief Summary
It was confirmed that hemodiafilter ABH-PA changed its removal performance depending on the amount of replacement fluid in both pre-dilution and post-dilution in HDF mode. Further, it was confirmed that the removal performance of ABH-PA tends to increase as the amount of replacement liquid increases. In addition, no significant difference was observed in the inflammatory maker level between the pre-dilution and the post-dilution.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 8
1) Patients on stable maintenance on-line hemodiafiltration therapy at least one month.
2) Patients with capable of obtaining blood flow rate >= 280 mL/min.
3) Patients who are undergoing hemodiafiltration with a hemodiafiler of membrane area >= 2.2m^2.
4) Patients who are undergoing hemodiafiltration for >= 4 hours per treatment.
5) Patients who are capable to participate in the study as outpatients.
6) Patients capable of understanding the informed consent form.
7) Patients >= 20 years and <85 years of age at the time of informed consent.
1)Patients requiring another blood purification therapy such as peritoneal dialysis other than
hemodiafiltration within this study period.
2)Patients with a medical history of anaphylaxis symptoms caused by polysulfone or polyvinylpyrrolidone (PVP).
3)Patients who will participate in other clinical trials that may influence the results of this study within this study period.
4)Patients in the opinion of the principal investigator to disqualify from participation.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction rate, Removal amount, Clear space, Albumin leakage, Transmembrane pressure, Antithrombotic property
- Secondary Outcome Measures
Name Time Method Inflammatory response